
|Videos|July 1, 2021
How the Phase 3 Trial Assessing an Investigational Dose of Semaglutide Injection for Type 2 Diabetes Was Conducted
Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses how the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes was conducted.
Advertisement
Pharmacy Times interviewed Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, on results from the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide (Ozempic; Novo Nordisk) injection in adults with type 2 diabetes.
During the discussion, Radin addresses how the phase 3 SUSTAIN FORTE trial was conducted.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
NK3 as a Drug Target: From Scientific Discovery to Guideline-Recognized Therapy
2
Sonrotoclax Plus Zanubrutinib Produces Deep MRD Responses in Treatment-Naive CLL
3
Orforglipron Reduces Body Weight Up to 14% in Women at Every Stage of Menopause
4
New Evidence Positions Finerenone as Foundational Therapy Across the CKD Spectrum
5































































































































